ArticleBMJ open2019
Cohort profile: role of lipoproteins in cardiovascular disease-the LipidCardio study.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.Nature medicine · 2024Pooled it
- Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.Circulation. Heart failure · 2023Trial
- Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.European heart journal · 2026Article
- Gut Microbial Metabolite Imidazole Propionate Impairs Endothelial Cell Function and Promotes the Development of Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Value of lipoprotein(a) in predicting severity of coronary artery stenosis in patients with chronic coronary artery disease: a cross-sectional study in Vietnam.Frontiers in cardiovascular medicine · 2025Article
- Lipoprotein(a) and Lung Function Are Associated in Older Adults: Longitudinal and Cross-Sectional Analyses.Biomedicines · 2024Article
- Polyvascular atherosclerosis and renal dysfunction increase the odds of cognitive impairment in vascular disease: findings of the LipidCardio study.European journal of medical research · 2024Article
- Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality.European heart journal · 2023Article
- The artificial sweetener erythritol and cardiovascular event risk.Nature medicine · 2023Article
- Epigenetic aging in patients diagnosed with coronary artery disease: results of the LipidCardio study.Clinical epigenetics · 2023Article
- Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a).Lipids in health and disease · 2022Article
- Potential protective effect against SARS-CoV-2 infection by APOE rs7412 polymorphism.Scientific reports · 2022Article
- Low muscle strength and increased arterial stiffness go hand in hand.Scientific reports · 2021Observational
- Exploring the Relationship of Relative Telomere Length and the Epigenetic Clock in the LipidCardio Cohort.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe LipidCardio Study was established for in-depth analyses of cardiovascular risk factors, providing well-defined cardiovascular and metabolic phenotypes. In particular, the role of lipoproteins in the pathobiological process and treatment of cardiovascular disease (CVD) will be a main focus.
participants1005 individuals aged 21 years and older undergoing cardiac catheterisation during 17 months at a tertiary academic cardiology centre were enrolled (troponin-positive acute coronary syndrome was exclusion criterion). The baseline data not only contain detailed phenotyping, broad biochemical parameters, genetic data, but also standardised personal and family history, a screening test for cognitive impairment, pulse wave analysis and measurements of hand grip strength, among others. Blood samples were stored in a biobank for future analyses. FINDINGS TO DATE: The mean age of the participants at enrolment was 70.9±11.1 years (70% male). Coronary angiography provided evidence of obstructive coronary artery disease (CAD) in 69.9% of participants. Those with evidence of CAD were significantly more likely to be male, inactive, diabetic and with a family history of CVD than participants without CAD.About 20% of patients had lipoprotein(a) (Lp(a)) concentrations above 106.9 nmol/L (fifth quintile). These patients had significantly increased odds of obstructive CAD compared with participants in quintiles 1-4 (crude OR 1.70, 95% CI 1.17 to 2.48, p=0.005). There was reasonable evidence that with increasing severity of CAD the odds of having elevated Lp(a) increased. We were able to replicate the established strong association between specified single nucleotide polymorphisms (SNPs) in the FUTURE PLANS: Mortality information will be obtained in 2 year intervals. Follow-up phone interviews will be conducted at 3 and 6 years after enrolment. We seek to cooperate with other researchers, for example, by sharing data and biobank samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.